EUVIMEDEUVIMED entdecken
Open Access

Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies

Enric Domingo iD, Caroline Kelly iD, Jennifer Hay iD, Owen Sansom, Noori Maka, Karin Oien, Tim Iveson iD, Mark Saunders, Rachel Kerr, Ian Tomlinson, Joanne Edwards, Andrea Harkin iD und 18 weitere

Journal of Clinical Oncology · 20.06.2024 · 42 (18) · 2207-2218

DOI: 10.1200/jco.23.01648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.06.2024. Verfasst von Enric Domingo und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Leucovorin, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Immunoscore (IS) is prognostic in stage III colorectal cancer (CRC) and may predict benefit of duration (6 v 3 months) of adjuvant infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. We sought to determine IS prognostic and predictive value in stage-III CRC treated with adjuvant FOLFOX or oral capecitabine and infusional oxaliplatin (CAPOX) in the SCOT and IDEA-HORG trials. METHODS Three thousand sixty-one cases had tumor samples, of which 2,643 (1,792 CAPOX) were eligible for IS testing. Predefined cutoffs (IS-Low and IS-High) were used to classify cases into two groups for analysis of disease-free survival (3-year DFS) and multivariable-adjusted hazard ratios (mvHRs) by Cox regression. RESULTS IS was determined in 2,608 (99.5%) eligible cases, with 877 (33.7%) samples classified as IS-Low. IS-Low tumors were more commonly high-risk (T4 and/or N2; 52.9% IS-Low v 42.2% IS-High; P < .001) and in younger patients ( P = .024). Patients with IS-Low tumors had significantly shorter DFS in the CAPOX, FOLFOX, and combined cohorts (mvHR, 1.52 [95% CI, 1.28 to 1.82]; mvHR, 1.58 [95% CI, 1.22 to 2.04]; and mvHR, 1.55 [95% CI, 1.34 to 1.79], respectively; P < .001 all comparisons), regardless of sex, BMI, clinical risk group, tumor location, treatment duration, or chemotherapy regimen. IS prognostic value was greater in younger (≤65 years) than older (>65 years) patients in the CAPOX cohort (mvHR, 1.92 [95% CI, 1.50 to 2.46] v 1.28 [95% CI, 1.01 to 1.63], P INTERACTION = .026), and in DNA mismatch repair proficient than deficient mismatch repair disease (mvHR, 1.68 [95% CI, 1.41 to 2.00] v 0.67 [95% CI, 0.30 to 1.49], P INTERACTION = .03), although these exploratory analyses were uncorrected for multiple testing. Adding IS to a model containing all clinical variables significantly improved prediction of DFS (likelihood ratio test, P < .001) regardless of MMR status. CONCLUSION IS is prognostic in stage III CRC treated with FOLFOX or CAPOX, including within clinically relevant tumor subgroups. Possible variation in IS prognostic value by age and MMR status, and prediction of benefit from extended adjuvant therapy merit validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsLeucovorinAntineoplastic Combined Chemotherapy ProtocolsFluorouracilOrganoplatinum CompoundsNeoplasm StagingHumansFemaleMaleMiddle AgedAgedPrognosisCapecitabinePredictive Value of TestsDisease-Free SurvivalOxaliplatinAdultChemotherapy, AdjuvantDeoxycytidine

Substanzen

LeucovorinFluorouracilOrganoplatinum CompoundsCapecitabineOxaliplatinDeoxycytidine

Autor:innen und Institutionen

  • Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • CRUK Beatson Institute of Cancer Research, Garscube Estate, Glasgow, United Kingdom.
  • CRUK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom.
  • Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • University of Southampton, Southampton, United Kingdom.
  • The Christie NHS Foundation Trust, Manchester, United Kingdom.

ORCID-Profile: Enric Domingo, Caroline Kelly, Jennifer Hay, Tim Iveson, Andrea Harkin, Viktor Koelzer, Alistair Easton, Ioannis Boukovinas, Ippokratis Messaritakis, Franck Pagès, Isabelle Boquet, Aurélie Catteau, Jérôme Galon, David N Church

Förderung

  • Cancer Research UK

Zitieren

APA

Domingo, E., Kelly, C., Hay, J., Sansom, O., Maka, N., Oien, K., Iveson, T., Saunders, M., Kerr, R., Tomlinson, I., Edwards, J., Harkin, A., Nowak, M., Koelzer, V., Easton, A., Boukovinas, I., Moustou, E., Messaritakis, I., Chondrozoumaki, M., …, & Church, D. N. (2024). Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies. Journal of Clinical Oncology, 42(18), 2207-2218. https://doi.org/10.1200/jco.23.01648

Vancouver

Domingo E, Kelly C, Hay J, Sansom O, Maka N, Oien K, et al. Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies. Journal of Clinical Oncology. 2024;42(18):2207-2218. doi:10.1200/jco.23.01648

BibTeX
@article{Domingo2024,
  author = {Domingo, Enric and Kelly, Caroline and Hay, Jennifer and Sansom, Owen and Maka, Noori and Oien, Karin and Iveson, Tim and Saunders, Mark and Kerr, Rachel and Tomlinson, Ian and Edwards, Joanne and Harkin, Andrea and Nowak, Marta and Koelzer, Viktor and Easton, Alistair and Boukovinas, Ioannis and Moustou, Eleni and Messaritakis, Ippokratis and Chondrozoumaki, Maria and Karagianni, Michaela and Pagès, Franck and Arnoux, Fanny and Lautard, Christelle and Lovera, Yoann and Boquet, Isabelle and Catteau, Aurélie and Galon, Jérôme and TransSCOT Consortium, TransSCOT Consortium and Souglakos, Ioannis and Church, David N},
  title = {Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {18},
  pages = {2207--2218},
  doi = {10.1200/jco.23.01648}
}
Kostenlos starten →